Cited by 2,098SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

SARS-CoV-2 vaccines in development

Open access

Krammer, Florian·2020·Nature

Open this paper in CoChat — free account

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2798-3

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Show all 101 references

Research works printed but not linked: 1

The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (The National Academies Press, 2020).

Sorted by citations

Items 201–300 of 1,004

Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
Maemura, T., Kuroda, M., Armbrust, T., Yamayoshi, S., Halfmann, P., & Kawaoka, Y. (2021) · mBio · doi:10.1128/mbio.01987-21 · Cited by 82
Gold nanoparticle conjugate‐based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS‐CoV‐2 in clinical samples using a smartphone‐based application
Prakashan, D., Shrikrishna, N. S., Byakodi, M., Nagamani, K., & Gandhi, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28416 · Cited by 84
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine
Krammer, F., Srivastava, K., the PARIS team, & Simon, V. (2021) · doi:10.1101/2021.01.29.21250653 · Cited by 116
Self-citation
Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
Das, S., Kar, S. S., Samanta, S., Banerjee, J., Giri, B., & Dash, S. K. (2022) · Immunologic Research · doi:10.1007/s12026-022-09265-0 · Cited by 82
An overview on inactivated and live‐attenuated SARS‐CoV‐2 vaccines
Khoshnood, S., Arshadi, M., Akrami, S., Koupaei, M., Ghahramanpour, H., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24418 · Cited by 76
Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection
Geng, Q., Tai, W., Baxter, V. K., Shi, J., Wan, Y., Zhang, X., Montgomery, S. A., Taft-Benz, S., Anderson, E. J., Knight, A. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009897 · Cited by 78
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Zhao, F., Zai, X., Zhang, Z., Xu, J., & Chen, W. (2022) · npj Vaccines · doi:10.1038/s41541-022-00597-4 · Cited by 83
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
Case, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.008 · Cited by 73
Sterilizing Immunity against SARS‐CoV‐2 Infection in Mice by a Single‐Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist‐Adjuvanted Recombinant Spike Protein Vaccine**
Jangra, S., Vrieze, J. D., Choi, A., Rathnasinghe, R., Laghlali, G., Uvyn, A., Herck, S. V., Nuhn, L., Deswarte, K., Zhong, Z., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202015362 · Cited by 77
Self-citation
High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro
Gard, A. L., Luu, R. J., Miller, C. R., Maloney, R., Cain, B. P., Marr, E. E., Burns, D. M., Gaibler, R. B., Mulhern, T. J., Wong, C. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94095-7 · Cited by 79
Engineered Cell Membrane‐Derived Nanoparticles in Immune Modulation
Yang, Y., Wang, K., Pan, Y., Rao, L., & Luo, G. (2021) · Advanced Science · doi:10.1002/advs.202102330 · Cited by 78
In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives
Sohail, M. S., Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.007 · Cited by 76
A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering
Zhu, J., Ananthaswamy, N., Jain, S., Batra, H., Tang, W.-C., Lewry, D. A., Richards, M. L., David, S. A., Kilgore, P. B., Sha, J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh1547 · Cited by 78
Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval
Tumban, E. (2020) · Viruses · doi:10.3390/v13010054 · Cited by 76
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 74
In vitro efficacy of Artemisia extracts against SARS-CoV-2
Nie, C., Trimpert, J., Moon, S., Haag, R., Gilmore, K. M., Kaufer, B. B., & Seeberger, P. H. (2021) · Virology Journal · doi:10.1186/s12985-021-01651-8 · Cited by 74
Role of genomics in combating COVID-19 pandemic
Saravanan, K. A., Panigrahi, M., Kumar, H., Rajawat, D., Nayak, S. S., Bhushan, B., & Dutt, T. (2022) · Gene · doi:10.1016/j.gene.2022.146387 · Cited by 81
SARS-CoV-2 spike S2-specific neutralizing antibodies
Li, C., & Chang, S. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2220582 · Cited by 73
A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., Alsoussi, W. B., et al. (2021) · doi:10.1101/2021.03.24.436864 · Cited by 72
Self-citation
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Schmitz, A. J., Turner, J. S., Liu, Z., Zhou, J. Q., Aziati, I. D., Chen, R. E., Joshi, A., Bricker, T. L., Darling, T. L., Adelsberg, D. C., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.013 · Cited by 62
Self-citation
Variants, vaccines and vaccination passports: Challenges and chances for travel medicine in 2021
Schlagenhauf, P., Patel, D., Rodriguez-Morales, A. J., Gautret, P., Grobusch, M. P., & Leder, K. S. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.101996 · Cited by 73
SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines
Suzuki, Y., & Gychka, S. G. (2021) · Vaccines · doi:10.3390/vaccines9010036 · Cited by 72
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
Kim, S., Wi, Y. M., Yun, S. Y., Ryu, J. S., Shin, J. M., Lee, E. H., Seo, K. H., Lee, S. H., & Peck, K. R. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e107 · Cited by 73
Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment
Yang, M., Qin, C., Tao, L., Cheng, G., Li, J., Lv, F., Yang, N., Xing, Z., Chu, X., Han, X., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122253 · Cited by 75
The find of COVID-19 vaccine: Challenges and opportunities
ElBagoury, M., Tolba, M. M., Nasser, H. A., Jabbar, A., Elagouz, A. M., Aktham, Y., & Hutchinson, A. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.12.025 · Cited by 71
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions
Shiakolas, A. R., Kramer, K. J., Wrapp, D., Richardson, S. I., Schäfer, A., Wall, S. C., Wang, N., Janowska, K., Pilewski, K. A., Venkat, R., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100313 · Cited by 75
Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model
Mohandas, S., Yadav, P. D., Shete-Aich, A., Abraham, P., Vadrevu, K. M., Sapkal, G., Mote, C., Nyayanit, D., Gupta, N., Srinivas, V. K., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102054 · Cited by 74
Antibody response to SARS‐CoV‐2 vaccination is extremely vivacious in subjects with previous SARS‐CoV‐2 infection
Callegaro, A., Borleri, D., Farina, C., Napolitano, G., Valenti, D., Rizzi, M., & Maggiolo, F. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26982 · Cited by 64
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques
Sui, Y., Li, J., Zhang, R., Prabhu, S. K., Andersen, H., Venzon, D. J., Cook, A., Brown, R., Teow, E., Velasco, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.148494 · Cited by 69
Assessment of avidity related to IgG subclasses in SARS-CoV-2 Brazilian infected patients
Moura, A. D., da Costa, H. H. M., Correa, V. A., Lima, A. K. D. S., Lindoso, J. Â. L., Gaspari, E. D., Hong, M. A., Cunha-Junior, J. P., & Prudêncio, C. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-95045-z · Cited by 75
Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle
Royal, J. M., Simpson, C. A., McCormick, A. A., Phillips, A., Hume, S., Morton, J., Shepherd, J., Oh, Y., Swope, K., DeBeauchamp, J., et al. (2021) · Vaccines · doi:10.3390/vaccines9111347 · Cited by 71
Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects
Zhang, Z., Shen, Q., & Chang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843928 · Cited by 69
COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers
Alhasan, K. A., Aljamaan, F., Temsah, M.-H. A., Alshahrani, F. S., Bassrawi, R. K., Alhaboob, A. A. N., Assiri, R., Alenezi, S., Alaraj, A., Alhomoudi, R. I., et al. (2021) · Healthcare · doi:10.3390/healthcare9111566 · Cited by 68
Clinical validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection
Nguyễn, L. T., Rananaware, S. R., Pizzano, B. L. M., Stone, B. T., & Jain, P. (2022) · Communications Medicine · doi:10.1038/s43856-021-00066-4 · Cited by 66
Bacillus Calmette-Guérin–induced trained immunity protects against SARS-CoV-2 challenge in K18-hACE2 mice
Zhang, B., Shuai, H., Gong, H., Hu, J., Yan, B., Yuen, T. T., Hu, Y., Yoon, C., Wang, X., Hou, Y., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157393 · Cited by 67
When Virtual Screening Yields Inactive Drugs: Dealing with False Theoretical Friends
Cerón‐Carrasco, J. P. (2022) · ChemMedChem · doi:10.1002/cmdc.202200278 · Cited by 66
In Search of the SARS-CoV-2 Protection Correlate: Head-to-Head Comparison of Two Quantitative S1 Assays in Pre-characterized Oligo-/Asymptomatic Patients
Rubio‐Acero, R., Castelletti, N., Fingerle, V., Olbrich, L., Bakuli, A., Wölfel, R., Girl, P., Müller, K., Jochum, S., Strobl, M., et al. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00475-x · Cited by 67
Therapeutic monoclonal antibodies for COVID-19 management: an update
Chavda, V. P., Prajapati, R., Lathigara, D., Nagar, B., Kukadiya, J., Redwan, E. M. M. M., Uversky, V. N., Kher, M. N., & Patel, R. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2078160 · Cited by 74
A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
Lu, M., Dravid, P., Zhang, Y., Trivedi, S., Li, A., Harder, O. E., Mahesh, K. C., Chaiwatpongsakorn, S., Zani, A., Kenney, A. D., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026153118 · Cited by 66
Nanozyme and Stimulated Fluorescent Cu-Based Metal–Organic Frameworks (Cu-MOFs) Functionalized with Engineered Aptamers as a Molecular Recognition Element for Thrombin Detection in the Plasma of COVID-19 Patients
Ali, G. K., & Omer, K. M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05232 · Cited by 66
Does improved digital governance in government promote natural resource management? Quasi-natural experiments based on smart city pilots
Chen, K., Li, Q., Shoaib, M., Ameer, W., & Jiang, T. (2024) · Resources Policy · doi:10.1016/j.resourpol.2024.104721 · Cited by 68
pH‐Responsive β‐Glucans‐Complexed mRNA in LNPs as an Oral Vaccine for Enhancing Cancer Immunotherapy
Luo, P.-K., Ho, H., Chiang, M., Chu, L., Chuang, Y., Lyu, P. C., Hu, I., Chang, W.-A., Peng, S., Jayakumar, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202404830 · Cited by 65
Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity
Weng, Y. L., Naik, S. R., Dingelstad, N., Lugo, M. R., Kalyaanamoorthy, S., & Ganesan, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-86471-0 · Cited by 65
Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes
Gattinger, P., Niespodziana, K., Stiasny, K., Sahanic, S., Tulaeva, I., Borochova, K., Dorofeeva, Y., Schlederer, T., Sonnweber, T., Höfer, G., et al. (2021) · Allergy · doi:10.1111/all.15066 · Cited by 64
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients
Carreño, J. M., Alshammary, H., Singh, G., Raskin, A. J., Amanat, F., Amoako, A. A., Gonzalez-Reiche, A. S., van de Guchte, A., PARIS study group, Awawda, M. H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103626 · Cited by 61
Self-citation
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting
Li, Z., Xiang, T., Liang, B., Deng, H., Wang, H., Feng, X., Quan, X., Wang, X., Li, S., Lu, S., et al. (2021) · Frontiers in Immunology · doi:10.2139/ssrn.3914631 · Cited by 66
Therapeutic RNA Delivery for COVID and Other Diseases
Dobrowolski, C. N., Paunovska, K., Hatit, M. Z. C., Lokugamage, M. P., & Dahlman, J. E. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002022 · Cited by 62
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review
Aleksova, A., Gagno, G., Sinagra, G., Beltrami, A. P., Janjusevic, M., Ippolito, G., Zumla, A. I., Fluca, A. L., & Ferro, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094526 · Cited by 64
Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids
Zhao, H., Wu, D., Nguyen, A., Li, Y., Adão, R. C., Valkov, E., Patterson, G. H., Piszczek, G., & Schuck, P. (2021) · iScience · doi:10.1016/j.isci.2021.102523 · Cited by 59
The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2
Huang, H., Zhang, C., Yang, S., Xiao, W., Zheng, Q., & Song, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.024 · Cited by 65
Lipopeptides for Vaccine Development
Hamley, I. W. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00258 · Cited by 62
Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research
Caronna, E., & Pozo‐Rosich, P. (2021) · Current Pain and Headache Reports · doi:10.1007/s11916-021-00987-8 · Cited by 62
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Chiuppesi, F., Nguyen, V. H., Park, Y., Contreras, H., Karpinski, V., Faircloth, K., Nguyen, J., Kha, M., Johnson, D., Martinez, J., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00436-6 · Cited by 61
The role of vaccines in the COVID-19 pandemic: what have we learned?
Krammer, F. (2023) · Seminars in Immunopathology · doi:10.1007/s00281-023-00996-2 · Cited by 66
Self-citation
Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine
Duarte, L. F., Gálvez, N. M. S., Iturriaga, C., Melo-González, F., Soto, J. A., Schultz, B. M., Urzua, M. D., González, L. A., Vázquez, Y., Ríos, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.742914 · Cited by 61
Humoral immune response after different SARS-CoV-2 vaccination regimens
Rose, R., Neumann, F., Grobe, O., Lorentz, T., Fickenscher, H., & Krumbholz, A. (2022) · BMC Medicine · doi:10.1186/s12916-021-02231-x · Cited by 62
An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants
Chi, X., Zhang, X., Pan, S., Yu, Y., Shi, Y., Lin, T., Duan, H., Liu, X., Chen, W., Yang, X., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00912-4 · Cited by 65
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Ashraf, M. U., Kim, Y., Kumar, S., Seo, D., Ashraf, M., & Bae, Y. (2021) · Vaccines · doi:10.3390/vaccines9020171 · Cited by 62
COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models
Conforti, A., Marra, E., Palombo, F., Roscilli, G., Ravà, M., Fumagalli, V., Muzi, A., Maffei, M., Luberto, L., Lione, L., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.011 · Cited by 55
Comprehensive Survey of Using Machine Learning in the COVID-19 Pandemic
El-Rashidy, N. M., Abdelrazek, S. M., Abuhmed, T., Amer, E., Ali, F., Hu, J. W., & El–Sappagh, S. (2021) · Diagnostics · doi:10.3390/diagnostics11071155 · Cited by 62
Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
Vanshylla, K., Fan, C., Wunsch, M., Poopalasingam, N., Meijers, M., Kreer, C., Kleipass, F., Ruchnewitz, D., Ercanoglu, M. S., Gruell, H., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.12.010 · Cited by 58
Efficacy of repurposed antiviral drugs: Lessons from COVID-19
Martı́nez, M. Á. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.02.012 · Cited by 65
Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates
Zhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00861-4 · Cited by 60
Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization
Sui, Y., Bekele, Y., & Berzofsky, J. A. (2021) · Pathogens · doi:10.3390/pathogens10020138 · Cited by 57
Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment
Martínez, M. Á. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635371 · Cited by 62
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
Cheng, M. H., Porritt, R. A., Rivas, M. N., Krieger, J., Ozdemir, A. B., Garcia, G., Arumugaswami, V., Fries, B. C., Arditi, M., & Bahar, İ. (2021) · Structure · doi:10.1016/j.str.2021.04.005 · Cited by 59
Transmission of SARS-CoV-2 from humans to animals and potential host adaptationPreprint
Tan, C. C. S., Lam, S. D., Richard, D., Owen, C. J., Berchtold, D., Orengo, C. A., Nair, M. S., Kuchipudi, S. V., Kapur, V., van Dorp, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.16.384743 · Cited by 62
Microarray patches enable the development of skin-targeted vaccines against COVID-19
Korkmaz, E., Balmert, S. C., Sumpter, T. L., Carey, C. D., Erdös, G., & Falo, L. D. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.022 · Cited by 60
Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection
Zang, J., Zhu, Y., Zhou, Y., Gu, C., Yi, Y., Wang, S., Xu, S., Hu, G., Du, S., Yin, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00315-9 · Cited by 59
Detection and discrimination of SARS-CoV-2 spike protein-derived peptides using THz metamaterials
Lee, S. H., Lee, Y. K., Lee, S., Kwak, J., Song, H. S., & Seo, M. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.113981 · Cited by 61
Single‐cell transcriptomic atlas reveals distinct immunological responses between COVID‐19 vaccine and natural SARS‐CoV‐2 infection
Wang, Y., Wang, X., Luu, L. D. W., Li, J., Cui, X., Yao, H., Zhang, X., Chen, S., 付锦, Wang, C., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28012 · Cited by 61
Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization
Chiba, S., Frey, S. J., Halfmann, P., Kuroda, M., Maemura, T., Yang, J. E., Wright, E., Kawaoka, Y., & Kane, R. S. (2021) · Communications Biology · doi:10.1038/s42003-021-02128-8 · Cited by 57
China COVID vaccine reports mixed results — what does that mean for the pandemic?
Mallapaty, S. (2021) · Nature · doi:10.1038/d41586-021-00094-z · Cited by 59
Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity
Bradley, B. T., Bryan, A. B., Fink, S. L., Goecker, E. A., Roychoudhury, P., Huang, M.-L. W., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00989-21 · Cited by 55
Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12–18 Years in Saudi Arabia
Alamer, E., Alhazmi, A., Qasir, N. A., Alamer, R. A., Areeshi, H., Gohal, G. A., Qadri, M. M., Hashem, A. M., & Algaissi, A. A. (2021) · Vaccines · doi:10.3390/vaccines9111297 · Cited by 57
Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination
Narayanaswamy, V., Pentecost, B. T., Schoen, C. N., Alfandari, D., Schneider, S. S., Baker, R., & Arcaro, K. F. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004661 · Cited by 58
What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?
Reig, S., Gouëllec, A. L., & Bleves, S. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.909731 · Cited by 63
Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses
Halfmann, P., Frey, S. J., Loeffler, K., Kuroda, M., Maemura, T., Armbrust, T., Yang, J. E., Hou, Y. J., Baric, R. S., Wright, E., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104341 · Cited by 54
Impact of South African 501.V2 Variant on SARS-CoV-2 Spike Infectivity and Neutralization: A Structure-based Computational AssessmentPreprint
Cheng, M. H., Krieger, J., Kaynak, B., Arditi, M., & Bahar, İ. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.10.426143 · Cited by 57
Is there a role for childhood vaccination against COVID‐19?
Eberhardt, C. S., & Siegrist, C. (2020) · Pediatric Allergy and Immunology · doi:10.1111/pai.13401 · Cited by 58
Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19
Dobaño, C., Ramírez‐Morros, A., Alonso, S., Vidal‐Alaball, J., Ruiz‐Olalla, G., Vidal, M., Rubio, R., Cascant, E., Parras, D., Melero, N. R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02032-2 · Cited by 58
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 64
Efficacy of COVID-19 vaccines: From clinical trials to real life
Deplanque, D., & Launay, O. (2021) · Therapies · doi:10.1016/j.therap.2021.05.004 · Cited by 57
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial
Pitisuttithum, P., Luvira, V., Lawpoolsri, S., Muangnoicharoen, S., Kamolratanakul, S., Sivakorn, C., Narakorn, P., Surichan, S., Prangpratanporn, S., Puksuriwong, S., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101323 · Cited by 56
Self-citation
Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B
Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj9815 · Cited by 56
Indoor versus outdoor transmission of SARS-COV-2: environmental factors in virus spread and underestimated sources of risk
Senatore, V., Zarra, T., Buonerba, A., Choo, K., Hasan, S. W., Korshin, G. V., Li, C., Ksibi, M., Belgiorno, V., & Naddeo, V. (2021) · Euro-Mediterranean Journal for Environmental Integration · doi:10.1007/s41207-021-00243-w · Cited by 56
COVID-19: Insights into Potential Vaccines
Loo, K.-Y., Letchumanan, V., Ser, H., Teoh, S. L., Law, J. W., Tan, L. T., Mutalib, N. A., Chan, K., & Lee, L. (2021) · Microorganisms · doi:10.3390/microorganisms9030605 · Cited by 59
Chemo‐Enzymatic Modification of the 5′ Cap Maintains Translation and Increases Immunogenic Properties of mRNA
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100352 · Cited by 56
Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2
Bajad, N. G., Swetha, R., Gutti, G., Sharma, A., Singh, M., Kumar, A., & Singh, S. K. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100026 · Cited by 58
Emerging Infection, Vaccination, and Guillain–Barré Syndrome: A Review
Koike, H., Chiba, A., & Katsuno, M. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00261-4 · Cited by 62
Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis
Kumar, R., Srivastava, Y., Muthuramalingam, P., Singh, S. K., Verma, G., Tiwari, S., Tandel, N., Beura, S. K., Panigrahi, A. R., Maji, S., et al. (2023) · Viruses · doi:10.3390/v15040856 · Cited by 57
Nucleic Acid-Based Technologies Targeting Coronaviruses
Le, T. K., Paris, C., Khan, K. S., Robson, F., Ng, W., & Rocchi, P. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.010 · Cited by 57
Implications of inadequate water and sanitation infrastructure for community spread of COVID-19 in remote Alaskan communities
Eichelberger, L., Dev, S., Howe, T. S., Barnes, D. L., Bortz, E., Briggs, B. R., Cochran, P. A. L., Dotson, A. D., Drown, D. M., Hahn, M. B., et al. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.145842 · Cited by 62
The evolutionary dynamics of endemic human coronaviruses
Jo, W. K., Drosten, C., & Drexler, J. F. (2021) · Virus Evolution · doi:10.1093/ve/veab020 · Cited by 60
A Machine-Generated View of the Role of Blood Glucose Levels in the Severity of COVID-19
Logette, E., Lorin, C., Favreau, C., Oshurko, E., Coggan, J. S., Casalegno, F., Sy, M. F., Monney, C., Bertschy, M., Delattre, É., et al. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.695139 · Cited by 58
SARS-CoV-2 exploits host DGAT and ADRP for efficient replication
Yuan, S., Yan, B., Cao, J., Ye, Z., Liang, R., Tang, K., Luo, C., Cai, J., Chu, H., Chung, T. W.-H., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00338-2 · Cited by 55
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
Wang, S., Wang, J., Yu, X., Jiang, W., Chen, S., Wang, R., Wang, M., Jiao, S., Wang, W., Wang, W., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03207-0 · Cited by 57
Understanding “Hybrid Immunity”: Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines
Epsi, N. J., Richard, S. A., Lindholm, D. A., Mende, K., Ganesan, A., Huprikar, N., Lalani, T., Fries, A. C., Maves, R. C., Colombo, R. E., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac392 · Cited by 59
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
Previous immunity shapes immune responses to SARS-CoV-2 booster vaccination and Omicron breakthrough infection risk
Pérez‐Alós, L., Hansen, C. B., Armenteros, J. J. A., Madsen, J. R., Heftdal, L. D., Hasselbalch, R. B., Pries‐Heje, M. M., Bayarri‐Olmos, R., Jarlhelt, I., Hamm, S. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41342-2 · Cited by 53

Authors: Krammer, F.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Krammer, Florian
ORCID: Krammer, Florian
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-09-23
Volume: 586
Issue: 7830
Pages: 516-527
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2798-3
OpenAlex: W3087924281
Cited by: 2,098
References: 101
Citations by year: 2026: 91 · 2025: 147 · 2024: 173 · 2023: 287 · 2022: 538 · 2021: 747 · 2020: 112
FWCI: 19.97
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zenodo (CERN European Organization for Nuclear Research) (cc-by)
Funders: JPB Foundation (2020-215611, HHSN272201400008C, 75N93019C00051)
Open Philanthropy Project (#2020-215611, 75N93019C00051, HHSN272201400008C)
National Institute of Allergy and Infectious Diseases (HHSN272201400008C), 75N93019C00051, 2020-215611, HHSN272201800048C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 vaccines, vaccine development, vaccine candidate, clinical trials, animal studies, vaccine safety, vaccine efficacy, COVID-19 pandemic
MeSH terms: Drug Development, COVID-19, COVID-19 Vaccines, Animals, Clinical Trials as Topic, Drug Industry, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Immunity, Mucosal, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 vaccines in development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks